201. Intermacs quarterly report analysis to monitor longitudinal outcomes in a centrifugal flow assist device.
- Author
-
Li, Song, Slaughter, Mark S., Hall, Shelley, Davis, Erin, Kappetein, Arie Pieter, Dedrick, Alexandra, Salerno, Christopher T., Pagani, Francis D., and Mahr, Claudius
- Subjects
- *
QUARTERLY reports , *STROKE , *HEART assist devices , *DELAY lines , *THROMBOSIS - Abstract
In June 2021, HVAD System distribution ceased due to observational data demonstrating increased mortality and neurological events compared to another commercial device, and a device malfunction with delay or failure to restart, especially in certain subpopulations. To assess ongoing risk for patients on support following subsequent device recalls, the manufacturer's Intermacs HVAD System 2022 Quarterly Reports were queried to identify mortality and adverse events trends in a contemporary cohort of 3110 primary HVAD implantations since October 2017, stratified by year-of-implant. Mean duration of support was 21 ± 16 months, with 33% alive on original device, 25% transplanted, 6% undergoing device exchange, 4% recovered, and 32% expired. Kaplan–Meier and event-per-patient-year estimates for survival, freedom from device explant, stroke, and pump thrombus were similar across year-of-implant. Following market withdrawal and recent device recalls, there appears to be no increase in mortality, stroke, pump thrombus, or explant for HVAD-supported patients. Quarterly report monitoring is ongoing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF